Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Medicine Matters Home Rheumatology

Rheumatology

Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population

ARTICLE: Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population AUTHORS: Christopher A Mecoli, Tak Igusa, Mengkun Chen, XingYao Wang, Jemima Albayda, Julie J Paik, Eleni… Read More »Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population

Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

ARTICLE: Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course AUTHORS: Ji Soo Kim, Adrianne Woods, Laura Gutierrez-Alamillo, Maureen Laffoon, Fredrick… Read More »Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

ARTICLE: Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis AUTHORS: Iago Pinal-Fernandez, Angela Quintana, Jose Cesar Milisenda, Maria Casal-Dominguez, Sandra Muñoz-Braceras, Assia Derfoul, Jiram Torres-Ruiz, Katherine Pak, Stefania Dell'Orso, Faiza Naz, Gustavo… Read More »Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

ARTICLE: Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis AUTHORS: Anne R Bass, Noha Abdel-Wahab, Pankti… Read More »Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

ARTICLE: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) AUTHORS: Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric… Read More »Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)